BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

PharmaEngine, Inc. 

16F, 237 Sung-Chiang Road

Taipei  Taiwan  104  Republic of China
Phone: 886-2-2515-8228 Fax: 886-2-2515-7558


SEARCH JOBS


Industry
Pharmaceutical






 Company News
PharmaEngine, Inc. Announces Achieving Patient Enrollment Goal in the Phase III Metastatic Pancreatic Cancer Study of PEP02 (MM-398) 8/29/2013 10:14:59 AM    More...
PharmaEngine, Inc. Release: Studies of Nanoliposomal Irinotecan (PEP02, MM-398) in Late Stage Pancreatic Cancer and Gastric Cancer Published in British Journal of Cancer and Annals of Oncology 8/28/2013 10:47:42 AM    More...
PharmaEngine, Inc. and Guangzhou BeBetter Medicine Technology Signed a Collaboration and Research Agreement 1/3/2013 9:25:24 AM    More...
PharmaEngine, Inc. Nabs Rights to Nanobiotix's Nanoparticle Radiotherapy Booster for Up to $57 Million 8/6/2012 7:54:44 AM    More...
PharmaEngine, Inc. and Merrimack Pharmaceuticals Inc. Enter into a Licensing and Collaboration Agreement; PharmaEngine Eligible for $220 Million Upfront and Milestone Payments Plus Royalties 5/9/2011 6:57:44 AM    More...
PharmaEngine, Inc. Receives Approval of US IND Application for a Phase II Study of PEP02 (Liposome Irinotecan Injection) in Pancreatic Cancer 12/3/2008 9:21:16 AM    More...
Xenova Group PLC (XNVA) Grants Licence To PharmaEngine, Inc. 10/19/2005 5:13:16 PM    More...

//-->